Tolerance of BNT162b2 mRNA COVI-19 vaccine in patients with a medical history of COVID-19 disease : A case control study
Copyright © 2021 Elsevier Ltd. All rights reserved..
INTRODUCTION: Studies evaluating BNT162b2 mRNA Covid-19 vaccine safety excluded subjects with a previous history of COVID-19 infection. The aim of our study was to focus on the tolerance of this vaccine this population.
METHODS: An anonymous self-reporting survey related to safety and tolerance of vaccine was completed by subjects 21 to 28 days after the first vaccine dose in two vaccination centers.
RESULTS: Subjects with prior COVID-19 disease history (n = 61) had higher systemic reactions than subjects without any previous history (n = 1987) (45.9% vs 29.7%, p = 0.01). Asthenia, headache and fever were significantly more frequent in COVID-19 + group than negative group (25.6% vs 15.2% p = 0.045, 19.7% vs 9.3% p = 0.01, 6.5% vs 0.9% p = 0.003 respectively). Grade of severity was higher in COVID-19 + than in COVID-19 - group (p = 0.03).
CONCLUSION: Our study confirms a higher risk of side effects in patients with preexisting SARS-CoV-2 disease but with a good overall tolerance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Vaccine - 39(2021), 32 vom: 22. Juli, Seite 4410-4413 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Baldolli, Aurelie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BNT162 Vaccine |
|---|
| Anmerkungen: |
Date Completed 19.07.2021 Date Revised 21.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.vaccine.2021.06.054 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327572930 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327572930 | ||
| 003 | DE-627 | ||
| 005 | 20231225201059.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.vaccine.2021.06.054 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1091.xml |
| 035 | |a (DE-627)NLM327572930 | ||
| 035 | |a (NLM)34210574 | ||
| 035 | |a (PII)S0264-410X(21)00804-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Baldolli, Aurelie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tolerance of BNT162b2 mRNA COVI-19 vaccine in patients with a medical history of COVID-19 disease |b A case control study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.07.2021 | ||
| 500 | |a Date Revised 21.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Ltd. All rights reserved. | ||
| 520 | |a INTRODUCTION: Studies evaluating BNT162b2 mRNA Covid-19 vaccine safety excluded subjects with a previous history of COVID-19 infection. The aim of our study was to focus on the tolerance of this vaccine this population | ||
| 520 | |a METHODS: An anonymous self-reporting survey related to safety and tolerance of vaccine was completed by subjects 21 to 28 days after the first vaccine dose in two vaccination centers | ||
| 520 | |a RESULTS: Subjects with prior COVID-19 disease history (n = 61) had higher systemic reactions than subjects without any previous history (n = 1987) (45.9% vs 29.7%, p = 0.01). Asthenia, headache and fever were significantly more frequent in COVID-19 + group than negative group (25.6% vs 15.2% p = 0.045, 19.7% vs 9.3% p = 0.01, 6.5% vs 0.9% p = 0.003 respectively). Grade of severity was higher in COVID-19 + than in COVID-19 - group (p = 0.03) | ||
| 520 | |a CONCLUSION: Our study confirms a higher risk of side effects in patients with preexisting SARS-CoV-2 disease but with a good overall tolerance | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 infection | |
| 650 | 4 | |a Tolerance | |
| 650 | 4 | |a Vaccine | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a N38TVC63NU |2 NLM | |
| 700 | 1 | |a Michon, Jocelyn |e verfasserin |4 aut | |
| 700 | 1 | |a Appia, Fanny |e verfasserin |4 aut | |
| 700 | 1 | |a Galimard, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Verdon, Renaud |e verfasserin |4 aut | |
| 700 | 1 | |a Parienti, Jean Jacques |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccine |d 1985 |g 39(2021), 32 vom: 22. Juli, Seite 4410-4413 |w (DE-627)NLM012600105 |x 1873-2518 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2021 |g number:32 |g day:22 |g month:07 |g pages:4410-4413 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.vaccine.2021.06.054 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2021 |e 32 |b 22 |c 07 |h 4410-4413 | ||